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Abstract: We examined the neuro/axono-protective potential of a novel poly (ADP-ribose) 
polymerase (PARP) inhibitor L-2286 in a rat impact acceleration brain injury model. Male 
Wistar rats (n = 70) weighing 300-350 grams were used to determine the most effective 
intracerebroventricular (i.c.v.) dose of L-2286 administered 30 min after injury, and to test 
the neuroprotective effect at two time points (immediately, and 30 min after injury). The 
neuroprotective effect of L-2286 was tested using immunohistochemical (amyloid 
precursor protein and mid-sized mouse anti-neurofilament clone RMO-14.9 antibody) and 
behavioral tests (beam-balance, open-field and elevated plus maze). At both time-points, a 
100 µg/rat dose of i.c.v. L-2286 significantly (p < 0.05) reduced the density of damaged 
axons in the corticospinal tract and medial longitudinal fascicle compared to controls. In 
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the behavioral tests, treatment 30 min post-injury improved motor function, while the level 
of anxiety was reduced in both treatment protocols.  
Keywords: PARP-inhibitor; impact acceleration model; traumatic brain injury  
 
1. Introduction  
Poly (ADP-ribose) polymerase (PARP) plays a central role in the caspase-independent apoptosis 
pathway mediated by apoptosis-inducing factor (AIF), an evolutionarily conserved mitochondrial 
flavoprotein that can be released from mitochondria after mitochondrial membrane depolarization [1]. 
AIF-mediated apoptosis occurs in neurons under conditions of oxidative stress [2], in experimental 
traumatic brain injury (TBI) [3] and brain ischemia [4]. PARP inhibition represents a therapeutic 
strategy targeting both necrosis, if administered early enough, and apoptosis after TBI [5].   
PARP-inhibitors, such as benzamide analogs and isoquinoline derivatives, have been used previously 
to investigate the role of this nuclear enzyme in traumatic brain injury [5-8]. Systemic administration 
of the PARP-inhibitor INH2BP improved functional outcome after TBI in mice, but higher doses 
further inhibiting PARP activity worsened memory performance [5]. The PARP-inhibitor, GPI 6150, 
was also shown to have a protective effect in an experimental model of TBI. Besson and coworkers [8] 
demonstrated that PARP-1 inhibition with the PARP-inhibitors phenanthridinone-based PJ34 and 
isoquinolinone-based INO-1001 efficiently inhibits TBI associated with lateral fluid percussion in rats.  
The recently developed quinazolinone derivative L-2286 (2-[(2-piperidin-1-ylethyl)thio]quinazolin-
4(3H)-one) is considered to be a potent inhibitor of ischemia-reperfusion-induced myocardial injury 
[9],  (Figure 1.).  The aim of the present study was to determine the dose-response curve for 
intracerebroventricular (i.c.v.) L-2286 in an impact-acceleration (IA) model of TBI, and then to 
develop an efficient post-injury administration paradigm by applying the most effective dose. 
Figure 1. Chemical structure of L-2286 [9]. 
 
2. Results and Discussion  
2.1. Dose-Response Curve of i.c.v. L-2286 after Impact Acceleration Injury 
In the first experiment, we found that 10 µg/rat of i.c.v. L-2286 was ineffective for reducing the 
density of amyloid precursor protein (APP) immunoreactive (IR) axons in the corticospinal tract 
(CSpT). Although 50 µg/rat of i.c.v. L-2286 reduced the density of damaged profiles, a significant 
difference could not be demonstrated. Ultimately, 100 µg/rat of i.c.v. L-2286 significantly reduced the 
APP-IR axons in CSpT (Figure 2).  Int. J. Mol. Sci. 2010, 11                       
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Figure 2. The effect of i.c.v. L-2286 administered in different doses 30 min after severe 
impact acceleration head injury on the density of APP immunopositive axons in the CSpT 
(** p < 0.01 compared to vehicle group). 
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2.2. Results of Immunohistochemical Analysis  
The immunohistochemical examination, and the following digital data assessment and statistical 
analysis, revealed that 100 µg/rat of i.c.v. L-2286 in both treatment paradigms significantly reduced 
the density of APP and mid-sized mouse anti-neurofilament clone RMO-14.9 (RMO-14) IR axons 
after head injury.  
Treatment immediately and 30 min post-injury reduced the density of APP-IR axons (damaged 
axons/mm
2) in both the CSpT and medial longitudinal fascicle (MLF) to a similar degree compared to 
vehicle-treated animals. Both treatment time points were effective in terms of significantly reducing 
the density of RMO-14-IR  axons in CSpT and MLF compared to vehicle-treated animals. However, 
immediate post-injury treatment seems to be more effective, since a significant difference was 
observed in the density of damaged axons in both CSpT and MLF compared to 30 min post injury 
(Figure 3-5). 
2.3. Effect of 100 µg/rat of i.c.v. L-2286 on Beam-Balance Test Performance after IA 
In the assessment  of the beam-balance test, sham-injured animals did not display any motor 
impairment. The vehicle-treated group had the worst motor performance of the four groups assessed. 
Both treatment paradigms improved the beam-balance performance. Immediate post-injury treatment 
significantly improved the motor performance at one hour. However, a statistically significant 
difference was not observed after this time-point in comparison to vehicle-treated rats; rats in this 
treatment group did not reach the maximal accessible score (1) during the seven-day period. The group 
treated 30 min post-injury reached the maximal accessible score on the fourth day. The motor 
performance of this group was significantly improved from the second examined time-point (one hour) 
up to the last time-point (seventh day) compared to the vehicle-treated group (Figure 6).  Int. J. Mol. Sci. 2010, 11                       
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Figure 3. APP-IR axonal profiles (arrows) from CspT two hours post-injury. Note that the 
density of damaged axons appears reduced in rats treated with 100 µg/rat of i.c.v. L-2286 
(B) compared to those treated with vehicle (A). 
 
Figure 4. Densities of APP-immunopositive axons in CSpT and MLF in animals treated 
with 5 µl/rat of i.c.v. vehicle and 100 µg/rat of i.c.v. L-2286 immediately and 30 min  
post-injury (**p < 0.01 compared to vehicle). 
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2.4. Effect of 100 µg/rat of i.c.v. L-2286 on Open-Field Performance after IA 
The open-field test measures altered motor performance and the level of anxiety. Results of the test 
showed that there were significantly fewer crossing and grooming activities in the vehicle-treated 
group than in the sham-injured group. Immediate post-injury treatment with L-2286 did not 
significantly improve any of the three examined parameters compared to vehicle-treated animals. 
However, L-2286 treatment 30 min post-injury significantly improved the number of grooming Int. J. Mol. Sci. 2010, 11                       
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activities compared to the vehicle-treated group, but without any effect on the another two parameters 
(crossing and rearing) (Figure 7). 
Figure 5.  Densities of RMO-14  immunopositive axons in CSpT and MLF in animals 
treated with 5 µl/rat of i.c.v. vehicle and 100 µg/rat of i.c.v. L-2286 immediately and  
30 min post-injury (**p < 0.01 compared to vehicle). 
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Figure 6. Effect of 100 µg/rat of i.c.v. L-2286 on beam-balance test scores from   
one hour to seven days after severe IA head injury (*p < 0.05 and **p < 0.01 compared to  
vehicle-treated animals). 
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2.5. Effect of 100 µg/rat of i.c.v. L-2286 on Elevated Plus-Maze Performance after IA 
Results of the elevated plus-maze test indicate that the vehicle-treated animals suffered from 
anxiety after injury. A statistically significant difference between the sham-injured and vehicle-treated 
groups was detected in the number of head dips in the open arm, time in the open arm, time in the 
closed arm, and the amount of grooming in the closed arm. The anxiety level was significantly lower 
in the L-2286-treated group than in the vehicle treated animals, since rats spent significantly more time 
in the "unsafe” open arm than in the “safe” closed arm. Interestingly, the group treated immediately Int. J. Mol. Sci. 2010, 11                       
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post-injury not only spent significantly more time in the open arm than the vehicle treated group, but 
also the sham-injured group, a finding not observed in rats treated 30 min post-injury. The vehicle-
treated and the latter group significantly differed only in the parameters of head dips in the open arm, 
time in the open arm and time in the closed arm (Figure 8–10). 
Figure 7. Effect of 100 µg/rat of i.c.v. L-2286 on grooming in open-field test (*p < 0.05 
compared to vehicle-treated animals). 
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Figure 8. Effect of 100 µg/rat of i.c.v. L-2286 on head dip in the elevated plus-maze test 
(*p < 0.05 compared to vehicle-treated animals). 
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2.6. Discussion 
In our study, we demonstrated that the novel PARP inhibitor L-2286 is capable of preventing both 
morphological (axonal) and neurobehavioral sequelae associated with severe TBI evoked in a rat IA 
head injury model.  
The  first stage of the study determined the effective dose of this new drug in a post-injury 
administration paradigm using immunohistochemical analysis of APP accumulation in CSpT. This 
assay was chosen as APP is recognized as the primary (classical) marker of diffuse axonal injury Int. J. Mol. Sci. 2010, 11                       
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(DAI) evoked by TBI. Intracerebroventricular treatment with different doses of L-2286 30 min post-
injury proved that 100 µg/rat is the most effective dose of those applied (10; 50; 100 µg).  
Figure 9. Effect of 100 µg/rat of i.c.v. L-2286 on time spent in the closed arm in the 
elevated plus-maze test (**p < 0.01 compared to vehicle-treated animals). 
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Figure 10. Effect of 100 µg/rat of i.c.v. L-2286 on time spent in the open arm in the 
elevated plus-maze test (**p < 0.01 compared to vehicle-treated animals). 
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In the second phase of the experiment, APP and RMO-14 immunohistochemistry was used to 
further elucidate the efficiency of 100 µg/rat of i.c.v. L-2286 administered at time points after TBI 
(immediately and 30 min post-injury). Both time points were effective in terms of significantly 
reducing the densities of damaged axons in CSpT and MLF. It should be noted, however, that in the 
case of RMO-14-IR axons, immediate post-injury treatment appeared to be far more effective, 
although this difference was not observed in APP-IR axons.  
To the best of our knowledge, this study is the first attempt to assess the efficacy of   
PARP-inhibition on DAI. Studies have thus far aimed at analyzing poly(ADP-ribose) 
immunohistochemistry [8] or changes in the volume of brain lesions [8,10] following TBI. Since Int. J. Mol. Sci. 2010, 11                       
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traumatic axonal injury (TAI) has two major morphological characteristics assessable by 
immunochemistry,  i.e., the formation of axonal bulbs (predominantly detected by APP-IR) and 
cytoskeletal alterations reflected in neurofilament compaction (RMO-14-IR) [11,12], which may also 
occur independently in subpopulations of injured axons, we applied both immunohistochemical 
strategies to detect diffuse axonal injury in a reliable fashion.  
Our qualitative and quantitative immunohistochemical results corroborate earlier observations that 
show the complexity of TAI pathogenesis. Specifically, we demonstrated that RMO-14 and APP-IR 
axon populations display different reactions to the same neuroprotective intervention, a finding well 
explained in the aforementioned studies. 
Based on the finding that there is a strong decrease in the density of damaged IR axonal profiles, we 
assessed the functional efficacy of the therapeutic strategies applied. Many articles have demonstrated 
that Marmarou’s impact acceleration model impairs cognitive and motor functions in rodents [13–15]. 
The neurobehavioral outcome after TBI has primarily been examined with beam-walking,  
beam-balance, inclined-plane, Morris water-maze and Barnes-maze tests [16–18]. In our study,   
motor-behavioral tests after administration of 100 µg/rat of i.c.v. L-2286 significantly improved motor 
function and decreased anxiety levels. Specifically, 100 µg/rat of i.c.v. L-2286 in the beam-balance 
test for motor performance after TBI shows that 100 µg/rat of i.c.v. L-2286 administered 30 min after 
injury is even more effective than the immediate post-injury treatment, a finding that requires further 
investigation. In the open-field test assessing motor performance and anxiety-levels, the crossing and 
grooming activity of the vehicle-treated group was significantly lower than that of the sham-injured 
animals. A dose of 100 µg/rat of i.c.v. L-2286 administered 30 min post-injury significantly improved 
the amount of grooming, while the six other monitored parameters were not affected. In the elevated 
plus-maze test, vehicle-treated animals displayed anxiety after the injury, spending less time in the 
“unsafe” open arm. Vehicle-treated rats showed a clear preference for the “safe” closed arm during 
this test compared to the sham-injured and drug-treated groups. Nevertheless they still displayed some 
curiosity as the number of head dips into open arm is significantly higher than that of the other groups. 
Rats that have been treated with 100 µg/rat of i.c.v. L-2286 immediately post-injury spent significantly 
more time in the open (“less safe”) arm than their controls, suggesting that this relative risk-taking 
behavior might be associated with a side-effect of the drug. This has been postulated by Satchell and 
coworkers [5], who demonstrated in their experiment that high-dose PARP-inhibitors worsened 
memory performance. Interestingly enough, this “side effect” disappeared in the group treated   
30 min post-injury.  
Application of PARP-inhibitors may be useful in the treatment of numerous neurodegenerative 
diseases. The brain is particularly susceptible to radical-mediated neuronal damage due to high levels 
of oxygen consumption, unsaturated fatty acids, and iron stores, combined with low antioxidant 
resources. Oxidative stress is a critical step in neuronal degeneration [19–21]. Iwashita and coworkers 
[21] studied a newly synthesized PARP-inhibitor, FR247304, and found that this drug could exhibit 
potent PARP-1 inhibition both in vitro  and  in vivo,  with significant neuroprotective properties 
following ischemia-reperfusion in rats. This suggests that this compound or its derivative could not 
only be an important tool to investigate the physiological role of PARP in neurodegenerative 
pathways, but also a therapeutic option for stroke and neurodegenerative disease. Int. J. Mol. Sci. 2010, 11                       
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Provided that PARP activation and nicotinamide-adenine-dinucleutide (NAD
+) depletion contribute 
to cell death, its absence or inhibition may prevent cell death associated with the apoptotic cascade and 
energy depletion. There is solid evidence for the beneficial effects of energy conservation (via NAD
+ 
conservation) with PARP-inhibition in ischemic insults to the brain [22–26], but this theory requires 
further investigation in TBI. PARP inhibition following TBI may be neuroprotective in the acute 
period (<2 h post-injury in the rodent), when PARP activity is elevated. Chronic inhibition of PARP as 
a neuroprotective strategy results in behavioral recovery, although it may differentially affect brain 
subregions.  
PARP-inhibitors have been shown to improve neurological outcome in models of head injury 
[5,6,8,10]. Satchell and coworkers [5] administered intraperitoneal (i.p.) INH2BP immediately after 
injury and one day after controlled cortical impact (CCI) brain injury in mice. They found improved 
Morris water-maze performance with no difference in contusion volume, hippocampal neuron 
survival, or motor performance. Examining the effect of i.p. INO-1001 30 min before and three times 
daily for three days after fluid percussion injury in rats, Besson and coworkers [8] found improved 
motor function. In Clark’s [10] experiments, INO-1001 reduced the latency in mice to find the hidden 
platform in Morris water-maze and increased the time spent in the target quadrant after CCI. Ding and 
coworkers [27] demonstrated that 3-aminobenzamide (3-AB), a selective inhibitor of PARP, 
significantly reduced brain damage after focal ischemia in rats and also improved impaired motor 
functions. PARP-inhibitor  1,5-isoquinolinediol,  treatment alleviates, but does not completely 
normalize, tail-flick and paw-withdrawal response latencies, mechanical and tactile withdrawal 
thresholds, and exaggerated flinching behavior in rats with short-term streptozotocin-induced diabetes 
[28]. In hypoglycemia, significant learning and memory deficits were identified with behavioral 
testing six weeks after injury. Animals treated with 3-AB after hypoglycemia did not show any 
significant deficit in their ability to locate the platform compared with sham-operated animals during 
either the visible or hidden platform trials. The behavioral and histological studies after hypoglycemia 
suggest that the neuroprotection provided by PARP inhibition leads to long-lasting preservation of 
neuronal survival and function [29]. 
As maintenance of energy homeostasis in the prevention of DAI has been proven to be of ample 
importance [30–33], it seemed logical to assess the efficacy of this novel PARP inhibitor (L-2286) in 
the widely used model of impact acceleration (diffuse) brain injury described by Marmarou.  
3. Experimental Section 
Sixty-eight adult male Wistar rats weighing 300-350 g (Charles River, Budapest, Hungary) were 
used for the experiments. Animals were housed in single cages under controlled  environmental 
conditions (22 °C, 12-12 h light-dark cycle) with food and water ad libitum for two weeks prior to the 
study. The experiments were carried out in accordance with regulations of the Hungarian Animal Care 
Committee (BA02/2000-26/2001). 
3.1. Injury Induction  
The injury protocol was the same in all experiments. All rats were first anesthetized in a bell jar for 
5 min with 4% isoflurane (Forane, Abott, Hungary) in 70% N2O and 30% O2. After endotracheal Int. J. Mol. Sci. 2010, 11                       
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intubation, rats were ventilated with 1.5% isoflurane in 70% N2O and 30% O2 (Inspira ASV, Harvard 
Apparatus USA). Arterial oxygen saturation was measured via pulse oximetry (Nonin 8600V), rectal 
and temporal temperatures were monitored and maintained at 37 °C with a feedback-controlled heating 
pad (FHC BOWDOINHAM ME 04008 USA Temperature Control). A midline incision was made to 
expose the skull from the bregma to the lambda sutures. A stainless steel disc (10 mm in diameter and 
3 mm thickness) was fixed centrally between the lambda and bregma sutures using cyanoacrylate. A 
450-g weight was dropped from 2 m onto the stainless disc fixed to the rat’s skull. After impact, the 
metal disc was removed and the animals were monitored during the recovery of spontaneous 
respiration. Sham animals were prepared for injury in the same fashion, but were not injured.  
3.2. Establishment of Dose-Response Curve for i.c.v. L-2286 
To establish the dose-response curve for L-2286, each rat (n = 5 in each group) was given a single 
bolus of 10, 50 or 100 µg/rat of L-2286 dissolved in 5 µL of physiological saline. The drug was 
administered i.c.v. 30 min after severe head injury through a craniotomy 1 mm posterior, 1.5 mm 
lateral and 3.5 mm deep relative to bregma. The vehicle group (n = 5) received i.c.v. 5 µL/rat of 
physiological saline. Two hours post-injury, animals were sacrificed for immunohistological 
assessment to determine the dose-response curve in terms of a reduction in the density of damaged IR 
axons in the corticospinal tract. 
3.3. Experimental Protocol to Test the Post-Injury Administration Regime 
Rats (n = 24) received a single 100 µg/rat bolus of i.c.v. L-2286 dissolved in 5 µL of physiological 
saline, while vehicle-treated animals were treated with i.c.v. 5 µL/rat of physiological saline. L-2286 
was administered either 0 min (n = 12) or 30 min (n = 12) after injury. Animals for histological 
analysis (n = 24) were sacrificed 2 h after brain injury. The remaining 30 animals survived 9 days post-
injury and underwent behavioral tests each day.  
3.4. Immunohistochemistry 
Two hours after injury, rats were sacrificed with i.p. sodium pentobarbital and transcardially 
perfused with 4% paraformaldehyde in Millonig's buffer. Brains were removed from the skull and 
immersed in the same fixative overnight (16-18 h). Five mm-wide blocks of the brain were cut out 
using a sagittal brain-blocking device (Braintree Scientific Inc.), which include the regions extending 
from the interpeduncular fossa to the first cervical segment and were immersed in the same fixative for 
24 h. Blocks were sectioned with a Vibratome Series 1500 (Neurobionic, Denmark) at a thickness of 
30 µm and collected in 0.1 M phosphate buffer in a semi-serial fashion. Adjacent sections were then 
processed for immunohistochemical detection of damaged axonal profiles.  Impaired axoplasmatic 
transport, long associated with TAI, was assessed by immunohistochemical detection of APP [11,33-
38]. APP is carried by fast axoplasmic transport and accumulates at the foci of disturbed axoplasmic 
transport. A polyclonal antiserum targeting the C-terminus of beta-APP was used for this purpose 
[37,38]. Sections adjacent to those single labeled for APP, were single labeled for the detection of 
neurofilament (NF) compaction, another marker of DAI [11,39-43]. To this end, RMO-14 antibody Int. J. Mol. Sci. 2010, 11                       
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was used, which is known to target an epitope on the rod domain of altered NF-M subunits exposed 
upon modification of the NF sidearms, an assumed consequence of calcium-induced enzymatic 
processes [39,41,43]. After blocking endogenous peroxidase activity and rinsing in phosphate buffered 
saline (PBS), the above-defined groups of sections were microwaved (300 W) in citrate buffer for 
antigen retrieval as previously described [44]. Sections were then rinsed in PBS containing 1% normal 
goat serum (NGS, for APP labeling (Zymed)) or 1% normal horse serum (NHS, for RMO-14 labeling 
(Zymed)) and were incubated for 35 min with 0.2% Triton X (Sigma Aldrich, Hungary) in 10% NGS 
or NHS in PBS, respectively (Sigma Chemical Co., St Louis, MO). After two quick rinses in PBS 
containing 1% NGS (or NHS in the case of RMO-14), sections were incubated overnight in rabbit anti-
APP antibody (1:500) (Zymed Laboratories, Hartford, CT) or in mouse monoclonal RMO-14 antibody 
(1:500) (Zymed Laboratories, Hartford, CT). On the following day after rinsing in PBS containing 1% 
NGS (or NHS), sections were incubated in biotinylated anti-rabbit immunoglobulin derived from goat 
(diluted 1:200 in 1% NGS/PBS) or in 1:400 dilution of biotinylated rat adsorbed anti-mouse 
immunoglobulin derived from horse for 60 min, followed by rinsing in PBS. After incubation in an 
avidin-biotin-peroxidase complex (ABC standard "Elite" kit, Vector, England, at a dilution of 1:100) 
and rinsing 3 × 10 min in PBS and 2 × 10 min in 0.1 M phosphate buffer, sections were processed for 
visualization of the immunohistochemical complex using 0.05% diaminobenzidine (DAB) and 0.01% 
hydrogen peroxide in 0.1 M phosphate buffer. The sections were subsequently mounted and cleared 
for routine light microscopic examination. 
3.5. Image Analysis 
APP or RMO-14 IR axonal profiles were examined using a NIKON light microscope interfaced 
with a SPOT RT digital camera and a computer-assisted image analysis system (IMAGE-PRO PLUS 
v5.0.1) in a blinded fashion. The area of CSpT and MLF was analyzed. Six sections containing both 
CSpT and MLF regions from each animal were captured and digitized at a magnification of 10×. A 
180,000 µm
2 grid was superimposed over the CSpT and adjacent MLF region, and all damaged axonal 
profiles within the grid were counted and expressed as density of APP or RMO-14-IR axons   
(IR-axons/mm
2). 
3.6. Behavioral Tests 
Behavioral tests were conducted one day before (beam-balance) and from 1 h to 9 days after injury. 
The trials were scored blind by a single observer. The behavioral tests were done during the light 
phase. Between each trial, all apparatus were cleaned with a 75% ethanol solution. 
3.6.1. Beam-Balance Test 
Before injury, animals were given repeated training until capable of balancing on the beam for three 
consecutive trials of 60 sec each. Rats were placed at the center of a 1.5-cm-wide square wooden 
bridge that was suspended 60 cm above a foam pillow. All animal groups were tested after the injury 
(one trial/rat) for 7 days (1 h and 1-7 days after injury) and scored from 1-6 on beam balance [45]. All 
trial scores from each group were averaged daily for statistical analysis. The scoring was as follows: 1: Int. J. Mol. Sci. 2010, 11                       
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balances with steady posture; 2: grasps the side of the beam and/or has unsteady movements; 3: hugs 
the beam or slips without falling; 4: attempts to balance on the beam but falls off; 5: drops over the 
beam or hangs on the beam and falls off and 6: does not attempt to balance on the beam. 
3.6.2. Open-Field Test 
The open-field test was used to measure spontaneous locomotor activity. The open-field is a box 
with a 70 × 70 cm floor and a height of 50 cm. On the eighth day post–injury, rats were brought into 
the experimental room. They remained in their transfer cages for 30 min, after which each subject was 
placed into the center of the open-field box. Crossing, rearing and grooming were recorded with a 
video camera during the 5-minute test.  
3.6.3. Elevated Plus-Maze Test 
The elevated plus-maze was used to measure anxiogenic behavior. The maze consisted of   
4 intersecting arms and was constructed from varnished wood. The maze was elevated 1 m above the 
floor. The arms of the maze were 45 cm long and 10 cm wide; the closed arms had walls on 3 sides 
that were 30 cm high, and the open arms did not have walls on any side. Nine days after the trauma, 
rats were placed one-by-one in the center of the maze facing one of the closed arms. An observer, who 
was seated 1.5 m from the apparatus, recorded with a video camera the number of head dips into the 
open arms, entries with the first limbs into the open arms, grooming in both the closed and open arms 
and the time in closed or open arms. 
3.6.4. Statistical Analysis 
ANOVA with Dunnett’s post hoc test was used to compare the density of immunopositive   
axonal-profiles (expressed as mean number/mm
2) between L-2286- and vehicle-treated animals. For 
beam-balance, the scores of each group were totaled and averaged daily. ANOVA with Dunn’s post 
hoc tests were used to compare the scores of experimental groups. For open-field, the number of 
crossings, rearings and the time spent in central and peripheral zones during the 5-minute test were 
analyzed. For elevated plus-maze, the number of head dips into the open arms, entries with the first 
limbs into the open arms, grooming in both closed and open arms and the time spent in closed or open 
arms were analyzed. Results of open-field and elevated plus-maze were analyzed with ANOVA and 
Dunnett’s post hoc tests. Differences were considered significant with a p value of 0.05. Statistical 
analysis was performed using Graph Pad Instat software. 
4. Conclusions 
Our results strongly suggest the neuroprotective effect of PARP inhibition; the heterogeneity of the 
results mandates further, detailed experiments that should shed light on the exact subcellular 
pathomechanism of this PARP inhibition. Specifically, we should elucidate the role of diffuse neural 
injury not assessed in the present experiments that may lay behind the observed motor-behavioral 
benefit provided by L-2286. To this end, further studies in different models, primarily in fluid Int. J. Mol. Sci. 2010, 11                       
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percussion head injury, are planned, while also assessing ultrastructural details, particularly 
mitochondrial integrity in the axonal bundles that are prone to diffuse TBI. 
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